© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
This video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia.
In this video, Farhad Ravandi-Kashani, MD, of the MD Anderson Cancer Center in Houston, discusses a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia (AML).
Ravandi-Kashani presented results of the study (abstract 815) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Related Content: